10-Q/APeriod: Q2 FY2004

AMERICAN INTERNATIONAL GROUP, INC. Quarterly Report (Amendment) for Q2 Ended Jun 30, 2004

Filed August 9, 2005For Securities:AIG

Summary

This filing is an amendment to American International Group, Inc.'s (AIG) Form 10-Q for the quarterly period ended June 30, 2004. The primary purpose of this amendment is to reflect the restatement of AIG's financial results for the quarterly and six-month periods ended June 30, 2004 and 2003. This restatement is a result of extensive internal reviews and investigations into the use of non-traditional insurance products and certain reinsurance transactions, which identified accounting errors and inappropriate transactions. These issues led to significant restatements across multiple prior periods and business segments, impacting reported revenues, expenses, reserves, and shareholder equity. The filing also highlights significant recent developments, including credit rating downgrades by major agencies from 'AAA' to 'AA' and 'Aaa' to 'Aa2', which increase borrowing costs and may impact AIG's competitive positioning. Furthermore, the company is subject to numerous ongoing regulatory investigations and civil actions, particularly concerning insurance brokerage practices and non-traditional insurance products, which could further impair its ability to engage in certain businesses and affect its reputation. Material weaknesses in internal control over financial reporting were also identified, and remediation is ongoing. The company anticipates not being able to access U.S. public capital markets in the near future.

Key Highlights

  • 1Restatement of Financial Statements: AIG has restated its financial results for multiple prior periods (2000-2004) due to accounting errors and inappropriate transactions identified during an internal review and subsequent investigations.
  • 2Significant Impact of Restatement: The restatement involves adjustments across various accounts, including risk transfer, loss reserves, net investment income, and deferred acquisition costs, leading to changes in reported revenues, expenses, and shareholder equity.
  • 3Credit Rating Downgrades: Major rating agencies (S&P, Moody's, Fitch) have downgraded AIG's credit ratings, leading to increased borrowing costs and potential competitive disadvantages.
  • 4Ongoing Regulatory Investigations: AIG faces multiple regulatory investigations and civil actions related to insurance brokerage practices and non-traditional insurance products, which could negatively impact its business operations and reputation.
  • 5Material Weaknesses in Internal Control: The company identified material weaknesses in its internal control over financial reporting, with remediation efforts underway.
  • 6Access to Capital Markets Restricted: AIG does not expect to access U.S. public capital markets in the near future due to ongoing filings and SEC reviews.
  • 7Increased Collateral Requirements: Credit rating downgrades have necessitated AIG to post approximately $1.16 billion in collateral with counterparties, with potential for further significant increases.

Frequently Asked Questions

This filing is an amendment to reflect the restatement of AIG's financial results for the quarterly and six-month periods ended June 30, 2004 and 2003. This restatement is due to accounting errors and inappropriate transactions identified during internal reviews and investigations.

The restatements have resulted in adjustments to revenues, expenses, reserves, and shareholder equity across multiple prior periods. Specific areas impacted include accounting for risk transfer, loss reserves, net investment income, and deferred acquisition costs.

The downgrades by major rating agencies have increased AIG's borrowing costs, may lessen its ability to compete in certain businesses, and have required the company to post significant amounts of collateral with counterparties. As of July 15, 2005, AIG had already posted approximately $1.16 billion in collateral, with potential for further significant calls.

AIG is subject to numerous ongoing regulatory investigations and civil actions concerning insurance brokerage practices and non-traditional insurance products. These investigations could impair the company's ability to engage in certain businesses, affect its product attractiveness, and potentially lead to further legal proceedings.